Skip to content
Search

Latest Stories

Omnicell secures deal with Hanmi Pharmaceutical to distribute new dispensing automation in Britain

Omnicell has expanded it existing range of automated medicines management and adherence solutions by entering into an agreement with Hanmi Pharm to distribute innovative tools across the UK’s retail pharmacy market.

The American healthcare technology company says the deal is "in line with Omnicell’s vision and appreciation that the retail pharmacy market wants choice through a more agnostic approach to automated medication adherence solutions."


The South Korean Hanmi Pharm-owned JVM model will support both blister and pouch adherence with the same level of detail and infrastructure Omnicell offers for its full range of solutions.

The model offers a flexible portfolio of hardware – from small desktop to large-scale models capable of handling between 300 to 576 cartridges – enabling it to meet the varying demands of pharmacies and allowing them to scale up or down models to suit their requirements.

“The JVM range of products provides an exceptional new offering for a variety of budgets across the retail pharmacy market, which further demonstrates Omnicell’s commitment to understanding and meeting the needs of our clients,” said Sara Dalmasso, general manager and vice president of Omnicell International.

“The last 18-24 months have placed immense pressure on the sector and this is another step in helping to make the day-to-day working lives of pharmacists easier and more efficient, and ultimately freeing up their valuable time to focus more on face-to-face patient interaction and care.”

The agreement is expected to expand Omnicell’s existing automated medication adherence solutions, while making it more accessible to different users.

Cyrus Hodivala, sales director, UK and Ireland, at Omnicell International, adds: “It is important for us to be constantly evolving our solutions in line with the changing dynamics of the retail pharmacy sector. Joining forces with Hamni Pharm – a leading, global pharmaceutical company – provides a welcome expansion of Omnicell’s portfolio for the UK market.

“With a shared and comprehensive expertise in the automation field, we are confident the new partnership will ensure Omnicell remains at the forefront of automation solutions. By enabling pharmacists to easily scale their business, our solutions will result in immediate improvements in medication adherence and patient outcomes.”

In January, Omnicell acquired Hub and Spoke Innovations.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
PHOENIX expands operations with new depot in Aberdeen

Representational image

Photo credit: PHOENIX

PHOENIX opens new depot in Aberdeen

PHOENIX has announced the opening of a new depot in Aberdeen to support its growing customer base in Scotland.

The pharmaceutical wholesaler already operates 13 depots across the UK, collectively delivering over 250 million packs of medicines each year.

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less